Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,123.58 +44.72 (+0.55%) Bitcoin USD
64,385.26 +640.19 (+1.00%) CMC Crypto 200
1,389.72 -6.82 (-0.49%)
ABBV Jun 2024 220.000 call
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 220.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 385 |
- Yahoo Finance Video
PCE reading, Microsoft, Alphabet jump on earnings: Yahoo Finance
Investors are digesting the Fed's preferred inflation measure after the release of the Personal Consumption Expenditures (PCE) index.Big Tech is coming to the rescue on Wall Street. Microsoft (MSFT) and Alphabet (GOOGL, GOOG) are jumping following their latest earning reports. Both companies topped expectations and were helped by their AI businesses. The news comes after a rough day for stocks, with a weaker-than-expected GDP report and earnings from companies such as Meta (META), sending markets deep in the red. Today, we will hear from big names, including ExxonMobil (XOM), Chevron (CVX), Colgate-Palmolive (CL), and AbbVie (ABBV). Yahoo Finance trending tickers include Intel (INTC), Snap (SNAP), and Roku (ROKU). Key guests include:9 a.m. ET - Brian Rose -UBS Global Wealth Management Senior US Economist10:40 a.m. ET - Chris Peterson, Newell Brands CEO11:20 a.m. ET - Patrick Gelsinger, Intel CEO
ReutersAbbVie lifts profit forecast after Skyrizi sales beat expectations
(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. Shares of AbbVie rose nearly 2.5% in premarket trading. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier.
- Reuters
AbbVie raises annual profit forecast on strong Skyrizi sales
AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier. Analysts on average expect annual profit of $11.10 per share, according to LSEG data.
